A critical review of chronic kidney disease as a risk factor for coronary artery disease

Sacco, 2016, The heart of 25 by 25: achieving the goal of reducing global and regional premature deaths from cardiovascular diseases and stroke: a modeling study from the American Heart Association and World Heart Federation, Circulation, 133, e674, 10.1161/CIR.0000000000000395 Wheeler, 2017, KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) foreword, Kidney Int. Suppl., 7, 1, 10.1016/j.kisu.2017.04.001 Hill, 2016, Global prevalence of chronic kidney disease–a systematic review and meta-analysis, PLoS ONE, 11, 10.1371/journal.pone.0158765 Keith, 2004, Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization, Arch. Intern. Med., 164, 659, 10.1001/archinte.164.6.659 Reiss, 2018, CKD, arterial calcification, atherosclerosis and bone health: Inter-relationships and controversies, Atherosclerosis., 278, 49, 10.1016/j.atherosclerosis.2018.08.046 Liu, 2014, Cardiovascular disease and its relationship with chronic kidney disease, Eur. Rev. Med. Pharmacol. Sci., 18, 2918 Levin, 1999, Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin, Am. J. Kidney Dis., 34, 125, 10.1016/S0272-6386(99)70118-6 Drüeke, 2006, Normalization of hemoglobin level in patients with chronic kidney disease and anemia, N. Engl. J. Med., 355, 2071, 10.1056/NEJMoa062276 Pfeffer, 2009, A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease, N. Engl. J. Med., 361, 2019, 10.1056/NEJMoa0907845 Lekawanvijit, 2014, Cardiorenal syndrome: acute kidney injury secondary to cardiovascular disease and role of protein-bound uraemic toxins, J. Physiol., 592, 3969, 10.1113/jphysiol.2014.273078 Dou, 2007, The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells, J. Thromb. Haemost., 5, 1302, 10.1111/j.1538-7836.2007.02540.x Lekawanvijit, 2012, Cardiorenal syndrome: the emerging role of protein-bound uremic toxins, Circ. Res., 111, 1470, 10.1161/CIRCRESAHA.112.278457 Neirynck, 2013, An update on uremic toxins, Int. Urol. Nephrol., 45, 139, 10.1007/s11255-012-0258-1 Schwarz, 2000, Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure, Nephrol. Dial. Transplant., 15, 218, 10.1093/ndt/15.2.218 Moe, 2008, Mechanisms of vascular calcification in chronic kidney disease, J. Am. Soc. Nephrol., 19, 213, 10.1681/ASN.2007080854 Rennenberg, 2009, Vascular calcifications as a marker of increased cardiovascular risk: a meta-analysis, Vasc Health Risk Manag., 5, 185, 10.2147/VHRM.S4822 Mizobuchi, 2009, Vascular calcification: the killer of patients with chronic kidney disease, J. Am. Soc. Nephrol., 20, 1453, 10.1681/ASN.2008070692 London, 2002, Arterial structure and function in end-stage renal disease, Nephrol. Dial. Transplant., 17, 1713, 10.1093/ndt/17.10.1713 Tozawa, 2002, Pulse pressure and risk of total mortality and cardiovascular events in patients on chronic hemodialysis, Kidney Int., 61, 717, 10.1046/j.1523-1755.2002.00173.x Manjunath, 2003, Level of kidney function as a risk factor for cardiovascular outcomes in the elderly, Kidney Int., 63, 1121, 10.1046/j.1523-1755.2003.00838.x Go, 2004, Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization, N. Engl. J. Med., 351, 1296, 10.1056/NEJMoa041031 Eisen, 2018, The association between eGFR in the normal or mildly impaired range and incident cadiovascular disease: Age and sex analysis, Eur J Intern Med., 54, 70, 10.1016/j.ejim.2018.05.015 Reis, 2002, Mild renal insufficiency is associated with angiographic coronary artery disease in women, Circulation, 105, 2826, 10.1161/01.CIR.0000021597.63026.65 Attar, 2019, Effect of Chronic Kidney Disease on Cardiovascular Events: An Epidemiological Aspect from SPRINT Trial, Iran J Kidney Dis., 13, 328 Culleton, 1999, Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency, Kidney Int., 56, 2214, 10.1046/j.1523-1755.1999.00773.x Garg, 2002, Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I, Kidney Int., 61, 1486, 10.1046/j.1523-1755.2002.00270.x Manjunath, 2003, Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community, J. Am. Coll. Cardiol., 41, 47, 10.1016/S0735-1097(02)02663-3 Muntner, 2002, Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States, J. Am. Soc. Nephrol., 13, 745, 10.1681/ASN.V133745 Reddan, 2002, Renal insufficiency and the risk of cardiovascular mortality, Kidney Int., 62, 10.1046/j.1523-1755.2002.00594.x Weiner, 2004, Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies, J. Am. Soc. Nephrol., 15, 1307, 10.1097/01.ASN.0000123691.46138.E2 Al Suwaidi, 2002, Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes, Circulation, 106, 974, 10.1161/01.CIR.0000027560.41358.B3 Shiraishi, 2014, Prognostic impact of chronic kidney disease and anemia at admission on in-hospital outcomes after primary percutaneous coronary intervention for acute myocardial infarction, Int Heart J., 55, 301, 10.1536/ihj.13-367 Wright, 2002, Acute myocardial infarction and renal dysfunction: a high-risk combination, Ann. Intern. Med., 137, 563, 10.7326/0003-4819-137-7-200210010-00007 Mueller, 2004, Renal function and long term mortality after unstable angina/non-ST segment elevation myocardial infarction treated very early and predominantly with percutaneous coronary intervention, Heart, 90, 902, 10.1136/hrt.2003.021741 Vidal-Petiot, 2020, Chronic Kidney Disease Has a Graded Association with Death and Cardiovascular Outcomes in Stable Coronary Artery Disease: An Analysis of 21,911 Patients from the CLARIFY Registry, J Clin Med., 9, 4, 10.3390/jcm9010004 Kashiyama, 2015, Coronary plaque progression of non-culprit lesions after culprit percutaneous coronary intervention in patients with moderate to advanced chronic kidney disease: intravascular ultrasound and integrated backscatter intravascular ultrasound study, Int. J. Cardiovasc. Imaging, 31, 935, 10.1007/s10554-015-0633-y Shlipak, 2002, Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients, Ann. Intern. Med., 137, 555, 10.7326/0003-4819-137-7-200210010-00006 Halkin, 2005, Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score, J. Am. Coll. Cardiol., 45, 1397, 10.1016/j.jacc.2005.01.041 Best, 2004, Impact of mild or moderate chronic kidney disease on the frequency of restenosis: results from the PRESTO trial, J. Am. Coll. Cardiol., 44, 1786 Azar, 2000, Impact of end-stage renal disease on clinical and angiographic outcomes after coronary stenting, Am. J. Cardiol., 86, 485, 10.1016/S0002-9149(00)00998-X Patti, 2018, Impact of chronic renal failure on ischemic and bleeding events at 1 year in patients with acute coronary syndrome (from the Multicenter START ANTIPLATELET Registry), Am. J. Cardiol., 122, 936, 10.1016/j.amjcard.2018.05.049 Chu, 2017, The management and prognostic factors of acute coronary syndrome: evidence from the Taiwan Acute Coronary Syndrome Full Spectrum Registry, Acta Cardiol Sin., 33, 329 Smith, 2006, Serum urea nitrogen, creatinine, and estimators of renal function: mortality in older patients with cardiovascular disease, Arch. Intern. Med., 166, 1134, 10.1001/archinte.166.10.1134 de Franca, 2018, Evaluation of the impact of chronic kidney disease on the survival of octogenarian patients submitted to percutaneous coronary intervention, Indian Heart J., 70, 848, 10.1016/j.ihj.2018.06.009 Pocock, 2019, Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry, Clin. Cardiol. Orvin, 2015, The proxy of renal function that most accurately predicts short-and long-term outcome after acute coronary syndrome, Am. Heart J., 169, 702, 10.1016/j.ahj.2015.01.012 Liu, 2014, Impact of renal dysfunction on long-term outcomes of elderly patients with acute coronary syndrome: a longitudinal, prospective observational study, BMC Nephrol., 15, 78, 10.1186/1471-2369-15-78 Anavekar, 2004, Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction, N. Engl. J. Med., 351, 1285, 10.1056/NEJMoa041365 Glynn, 2007, Chronic kidney disease and mortality and morbidity among patients with established cardiovascular disease: a West of Ireland community-based cohort study, Nephrol. Dial. Transplant., 22, 2586, 10.1093/ndt/gfm222 Melloni, 2016, Impact of chronic kidney disease on long-term ischemic and bleeding outcomes in medically managed patients with acute coronary syndromes: Insights from the TRILOGY ACS Trial, Eur Hear J Acute Cardiovasc Care., 5, 443, 10.1177/2048872615598631 Torres, 2017, Long-term prognosis of chronic kidney disease in non-ST elevation acute coronary syndrome treated with invasive strategy, Nefrol (English Ed., 37, 276, 10.1016/j.nefroe.2017.06.001 Weiner, 2004, Kidney disease as a risk factor for recurrent cardiovascular disease and mortality, Am. J. Kidney Dis., 44, 198, 10.1053/j.ajkd.2004.04.024 Nagashima, 2013, Chronic kidney disease and long-term outcomes of myocardial infarction, Int. J. Cardiol., 167, 2490, 10.1016/j.ijcard.2012.04.049 Nemoto, 2014, Impact of continuous deterioration of kidney function 6 to 8 months after percutaneous coronary intervention for acute coronary syndrome, Am. J. Cardiol., 113, 1647, 10.1016/j.amjcard.2014.02.019 Herzog, 1998, Poor long-term survival after acute myocardial infarction among patients on long-term dialysis, N. Engl. J. Med., 339, 799, 10.1056/NEJM199809173391203 Sørensen, 2002, The prognostic importance of creatinine clearance after acute myocardial infarction, Eur. Heart J., 23, 948, 10.1053/euhj.2001.2989 Weiner, 2006, Cardiovascular outcomes and all-cause mortality: exploring the interaction between CKD and cardiovascular disease, Am. J. Kidney Dis., 48, 392, 10.1053/j.ajkd.2006.05.021 Hira, 2018, Care of Patients With Chronic Kidney Disease Presenting With Acute Coronary Syndrome: Improved, But Not Good Enough, Am. Heart Assoc., 10.1161/JAHA.118.011254 Bagai, 2018, Temporal Trends in Utilization of Cardiac Therapies and Outcomes for Myocardial Infarction by Degree of Chronic Kidney Disease: A Report From the NCDR Chest Pain–MI Registry, J Am Heart Assoc., 7, 10.1161/JAHA.118.010394 Shroff, 2012, Am. Heart J., 163, 399, 10.1016/j.ahj.2011.12.002 Carrero, 2017, Long-term versus short-term dual antiplatelet therapy was similarly associated with a lower risk of death, stroke, or infarction in patients with acute coronary syndrome regardless of underlying kidney disease, Kidney Int., 91, 216, 10.1016/j.kint.2016.09.014 Khedri, 2017, Systematic underutilisation of secondary preventive drugs in patients with acute coronary syndrome and reduced renal function, Eur J Prev Cardiol., 24, 724, 10.1177/2047487317693950 Beattie, 2001, Determinants of mortality after myocardial infarction in patients with advanced renal dysfunction, Am. J. Kidney Dis., 37, 1191, 10.1053/ajkd.2001.24522 Rozenbaum, 2017, The effect of admission renal function on the treatment and outcome of patients with acute coronary syndrome, Cardiorenal Med., 7, 169, 10.1159/000455239 Lutz, 2014, Haemostasis in chronic kidney disease, Nephrol. Dial. Transplant., 29, 29, 10.1093/ndt/gft209 P. Boccardo, G. Remuzzi, M. Galbusera, Platelet dysfunction in renal failure, in: Seminars in thrombosis and hemostasis. Copyright© 2004 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New…; 2004, pp. 579–589. Mehran, 2010, A risk score to predict bleeding in patients with acute coronary syndromes, J. Am. Coll. Cardiol., 55, 2556, 10.1016/j.jacc.2009.09.076 Gaspari, 1987, Aspirin prolongs bleeding time in uremia by a mechanism distinct from platelet cyclooxygenase inhibition, J Clin Invest., 79, 1788, 10.1172/JCI113020 Keltai, 2007, Renal function and outcomes in acute coronary syndrome: impact of clopidogrel, Eur J Cardiovasc Prev Rehabil., 14, 312, 10.1097/01.hjr.0000220582.19516.a6 Huang, 2013, Contemporary management of coronary artery disease and acute coronary syndrome in patients with chronic kidney disease and end-stage renal disease, Acta Cardiol Sin., 29, 132 Palmer, 2012, Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis, Ann. Intern. Med., 156, 445, 10.7326/0003-4819-156-6-201203200-00007 Charytan, 2006, The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease, Kidney Int., 70, 2021, 10.1038/sj.ki.5001934 Group SR, 2015, A randomized trial of intensive versus standard blood-pressure control, N. Engl. J. Med., 373, 2103, 10.1056/NEJMoa1511939 Covic, 2016, SPRINT: the study nephrologists might take with a grain of salt, J Clin Hypertens., 18, 1185, 10.1111/jch.12866 Ettehad, 2016, Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis, Lancet, 387, 957, 10.1016/S0140-6736(15)01225-8 Lonn, 2016, Blood-pressure lowering in intermediate-risk persons without cardiovascular disease, N. Engl. J. Med., 374, 2009, 10.1056/NEJMoa1600175 Group AS, 2010, Effects of intensive blood-pressure control in type 2 diabetes mellitus, N. Engl. J. Med., 362, 1575, 10.1056/NEJMoa1001286 Williams, 2018, 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH), Eur. Heart J., 39, 3021, 10.1093/eurheartj/ehy339 Whelton, 2018, 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults, J. Am. Coll. Cardiol., 71, e127, 10.1016/j.jacc.2017.11.006 Cheung, 2021, Executive summary of the KDIGO 2021 Clinical Practice Guideline for the management of Blood Pressure in Chronic Kidney Disease, Kidney Int., 99, 559, 10.1016/j.kint.2020.10.026 Mach, 2020, 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS), Eur. Heart J., 41, 111, 10.1093/eurheartj/ehz455 Arnett, 2019, Circulation, 140, e596 Trialists, 2010, Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials, Lancet, 376, 1670, 10.1016/S0140-6736(10)61350-5 McCormack, 2016, Very low LDL-C levels may safely provide additional clinical cardiovascular benefit: the evidence to date, Int. J. Clin. Pract., 70, 886, 10.1111/ijcp.12881 Cannon, 2015, Ezetimibe added to statin therapy after acute coronary syndromes, N. Engl. J. Med., 372, 2387, 10.1056/NEJMoa1410489 Schwartz, 2018, Alirocumab and cardiovascular outcomes after acute coronary syndrome, N. Engl. J. Med., 379, 2097, 10.1056/NEJMoa1801174 Sabatine, 2017, Evolocumab and clinical outcomes in patients with cardiovascular disease, N. Engl. J. Med., 376, 1713, 10.1056/NEJMoa1615664 Sharp Collaborative Group, 2010, Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease, Am. Heart J., 160, 785, 10.1016/j.ahj.2010.08.012 Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease, Kidney Int. Suppl. 3 (2013) 259–305. Ray, 2009, Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials, Lancet, 373, 1765, 10.1016/S0140-6736(09)60697-8 Cosentino, 2020, Eur. Heart J., 41, 255, 10.1093/eurheartj/ehz486 Group A to CCR in DS, 2008, Effects of intensive glucose lowering in type 2 diabetes, N. Engl. J. Med., 358, 2545, 10.1056/NEJMoa0802743 Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group, KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease, Kidney Int. 98(4S) (2020) S1–S115. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group, KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD), Kidney Int. Suppl. (2011) 7(1) (2017) 1–59. Chertow, 2012, Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis, N. Engl. J. Med., 367, 2482, 10.1056/NEJMoa1205624 Rakhit, 2006, Effect of aggressive risk factor modification on cardiac events and myocardial ischaemia in patients with chronic kidney disease, Heart, 92, 1402, 10.1136/hrt.2005.074393 Bangalore, 2020, Management of coronary disease in patients with advanced kidney disease, N. Engl. J. Med., 382, 1608, 10.1056/NEJMoa1915925